|
|
5/31/2006 12:18:19 PM ET
SWISS MEDICA RETAINS EMERGING MARKETS CONSULTANTS AS INVESTOR RELATIONS CONSULTANTS
AND PROVIDES DETAILS ON JUNE 5th INVESTOR CONFERENCE CALL
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
May 31, 2006
Toronto, Canada – Swiss Medica, Inc. (OTC BB: SWME) announced today that Emerging Markets Consulting,
LLC has been retained to provide investor relations services for the Company.
Raghu Kilambi, CEO of Swiss Medica stated “I am excited to have Jim Painter and Emerging Markets Consulting
join forces with Swiss Medica and share the unique story about our company and our revolutionary patented,
clinically tested all natural chronic ailment products. The investment community needs to know more information
about micro-cap companies that have real products, revenues and strong management teams. Swiss Medica is
a growing company with tremendous potential and promise whose story needs to be in front of more investors."
James S. Painter, CEO of Emerging Markets Consulting stated, "We are thrilled to work with Swiss Medica and
be able to get involved in marketing their company when their share price is so low. Our clients and the
investment community are always looking for companies with strong and experienced management teams, viable
business plans and products that have potential for huge growth. We believe the Swiss Medica story will be very
well received by the investment community."
Swiss Medica’s management will host a conference call on Monday, June 5, 2006 at 4:00 pm EST to discuss the
Company’s first quarter highlights and go forward strategy. Callers from the Toronto area are invited to dial 416-
695-5259 at that time to participate. All other callers are invited to dial 1-877-888-4605 to participate. The
conference will also be webcast with a direct link from www.swissmedica.com.
Please email questions you would like addressed during the conference call to djones@swissmedica.com.
About Emerging Markets Consulting, LLC
Emerging Markets Consulting, LLC specializes in bringing little known companies to the attention of the financial
community. EMC is actively focused on a carefully selected group of quality clients. EMC specializes in providing
the highest level of professional service to only the most exciting companies on the market. Please visit EMC on
the web to receive updates on clients at www.emergingmarketsllc.com.
About Swiss Medica, Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be
a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available
throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit
www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica launched the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1) over-the-
counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently
awarded O24 Fibromyalgia™ their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the
long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of
the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
who used the placebo. Customers can visit www.O24zone.com. for information on O24 Fibromyalgia™ and to
order the product online.
Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS
Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:
www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
For more information, please contact:
Swiss Medica, Inc.
Investor Relations Contact:
David Jones
1-866-485-4243
djones@swissmedica.com
|
|
